Meridian Bioscience (VIVO) Completes Acquisition of Magellan Biosciences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Canaccord Genuity Remains Sidelined Following Meridian Bioscience's (VIVO) Announced Magellan Diagnostics Acquisition
March 28, 2016 10:17 AM EDTCanaccord Genuity reiterated a Hold rating on Meridian Biosciences (NASDAQ: VIVO), and raised the price target to $19.00 (from $18.00), following the company's announced acquisition of Magellan Diagnostics. The acquisition marks VIVO's first material acquisition in nearly 6 years. Boston-based Magellan Diagnostics offers the only rapid (3-minute),... More
